Shinji Nakamura

Discovery of phenylpyrrolidine derivatives as a novel class of retinol binding protein 4 (RBP4) reducers.

A. Mizukami, N. Cho, S. Kasai, 2021, Bioorganic & medicinal chemistry.

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.

H. Kokubo, H. Oki, T. Taniguchi, 2017, Journal of medicinal chemistry.

TAK-137, an AMPA-R potentiator with little agonistic effect, has a wide therapeutic window

S. Sogabe, Y. Kosugi, T. Kaku, 2018, Neuropsychopharmacology.